Dr. John Cush RheumNow
1 year 7 months ago
Eric Dein @ericdeinmd
#RNL2025 Treatment of sclerosing skin conditions: Active inflammation? Sclerotic? Atrophic? Target based on activity, depth of involvement and other disease involvement
Dr. John Cush RheumNow
1 year 7 months ago
MD Survey: Who should manage patients with hidradentis supprativa?
Dr. John Cush RheumNow
1 year 7 months ago
Full read, comprehensive review of Hidradenitis Supprativa in Lancet Feb 1, 2025
Common assn; DM, IBD, Smoking, Obesity, metabolic syndr, NASH, SpA, RA
FDA approved Rx: Adalimumab, Secukinumab, Bimekizumab https://t.co/5Tb8on21E0 https://t.co/BLu6Zaejj5
Dr. John Cush RheumNow
1 year 7 months ago
Janet Pope @Janetbirdope
#ClinicalPearl Insights into #fibrosing #skin conditions Inflammatory Fibrotic Atrophy We treat the #inflammation but need to determine if lesions are active or not Bx May not discern #dx Heidi Jacobe #RNL2025 https://t.co/dG1k4fm4aO https://t.co/5TowCCDiTt
Dr. John Cush RheumNow
1 year 7 months ago
TheDaoIndex @KDAO2011
@drcharitydean on emerging public health threats including H5N1 & communicable dz. We need to be monitoring for human to human disease transmissions. There is a high level of concern by large business as they recognize this will affect the supply chain.… https://t.co/T3TZ7LtHQi https://t.co/Ar85A0EcW4
Dr. John Cush RheumNow
1 year 7 months ago
That's not my problem - or is it? Multimorbidity in RA
RA can look so easy on the television commercials where patients appear young, healthy, and vibrant on the advertised treatment.
https://t.co/B7WUiysNSE https://t.co/nczmoIBfOb
Dr. John Cush RheumNow
1 year 7 months ago
The POWER of #plaquenil
#Hydroxychloroquine works in #rheumatic #diseases by
Old answer
👇
Alters liposomal membranes 🤷♀️
NEW ANSWER
Inhibits TLR signalling 🔥
#RNL2025 Mary *Peggy Crow #SLE #systemic #lupus #erythematosus https://t.co/j2YQjVIpcy
Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Dr. John Cush RheumNow
1 year 7 months ago
Eric Dein @ericdeinmd
B England
75% of RA pts have multi-morbidity
Pts develop multi-morbidity BEFORE the onset of RA
Should we have different goals: Prioritize LDA over remission in pts w multimorbidity
Collaborate w PCP: one size doesn't fit all, do something better than… https://t.co/RIe7BhSgvJ https://t.co/4dVdR088XF
Dr. John Cush RheumNow
1 year 7 months ago
TheDaoIndex @KDAO2011
A practical clinic-based approach to assessing CVD, CA screening, lung disease, infections for rheums by Dr Bryant England who offers us menus.. start by asking about symptoms. #RNL2025
https://t.co/AcQDJS870I https://t.co/UCyDOF2GRZ
Dr. John Cush RheumNow
1 year 7 months ago
Adela Castro @AdelaCastro222
Multimorbidity in Rheumatoid Arthritis:
-Affects >75% of pts
-Reduces quality of life and increases mortality
-Highly associated w/ D2T RA
-Requires multidisciplinary care teams (PCP, specialists, case management, PT)
-Management should start early… https://t.co/Sshm8CUWOA https://t.co/W9dojZT99T
Dr. John Cush RheumNow
1 year 7 months ago
Jeffrey Curtis @RADoctor
Great talk at #RNL2025 by Dr Una Makris on managing geriatric rheumatology patients. How often do we under-treat #Rheumatoid arthritis patients with advanced therapies because we fall into the trap of ageism? https://t.co/kWLxt15n4X https://t.co/cmLjqigNol
Dr. John Cush RheumNow
1 year 7 months ago
Janet Pope @Janetbirdope
Dispel the #myth #rheumatoid #arthritis is NOT Just a disease of Young and middle aged Elderly PREVALENT #RA Pts and 👇 INCIDENT Pts in >65yrs is skyrocketing 🚀 Need #Rx goals and equitable #Rx Uma Makris #RNL2025
https://t.co/3IsVKTSEyy
